Roche's Kadcyla beats out Herceptin in Phase 3

The data should help to advance the Swiss pharma's plans to reinforce its breast cancer franchise as biosimilar competition to Herceptin creeps in.

By Suzanne Elvidge • Oct. 16, 2018

Confronting pharma, Trump admin seeks price disclosure in drug ads

HHS chief Alex Azar announced the much-anticipated proposal Monday, dismissing a new pledge from trade lobby PhRMA as insufficient.

By Ned Pagliarulo , Andrew Dunn • Updated Oct. 15, 2018

Explore the Trendline➔

Commercialization

New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.

By BioPharma Dive staff

Under pressure, drugmakers give an inch on DTC drug ads

Members of the trade group PhRMA will soon point consumers to drug cost information in direct-to-consumer TV ads, but won't go so far as to include prices upfront.

By Ned Pagliarulo • Updated Oct. 15, 2018

J&J snaps up key label expansion for Xarelto

Regulators cleared the drug to reduce the risk of major cardiovascular events for certain patients, which could help its position against market leading Eliquis.

By Suzanne Elvidge • Oct. 15, 2018

Mylan's generic Copaxone wins in court, but market barriers remain

A court of appeals confirmed Teva's patents for the blockbuster multiple sclerosis drug are invalid, in turn strengthening Mylan's hand.

By Suzanne Elvidge • Oct. 15, 2018

With latest deal, AbbVie keeps another Humira biosimilar at bay

An agreement with Novartis allows for the Swiss pharma's copycat version to launch in the U.S. in September 2023, behind rivals from Amgen and others. 

By Jacob Bell • Oct. 11, 2018

DOJ clears CVS-Aetna union

Approval of the $69 billion deal comes with a condition to sell Aetna's Medicare Part D business. 

By Samantha Liss • Oct. 10, 2018

Price increases on top drugs drove majority of recent growth, analysis finds

Over the past three years, roughly 60% of the growth in U.S. sales for four dozen top-selling drugs came via price increases, according to numbers crunched by investment firm Leerink.

By Ned Pagliarulo • Oct. 10, 2018

Prescription drug spending, prices moderate in Q2

Spending on healthcare services, however, ticked up in the second quarter to post a 4.9% year-over-year growth rate. 

By Les Masterson • Oct. 8, 2018

Approval puts Bausch step closer to dermatology turnaround

It's welcome news for Bausch's struggling dermatology portfolio, which saw the FDA reject another key psoriasis candidate in June.

By Jacob Bell • Oct. 8, 2018

Merck gets a shot in the arm with expanded label for Gardasil

The HPV vaccine is now also approved for adults aged 27 through 45 years old, widening the addressable market for Merck.

By Suzanne Elvidge • Oct. 8, 2018

Gilead reaches deal for Yescarta coverage in England

For now, the CAR-T therapy will be provided through NHS' Cancer Drugs Fund, after a government agency judged it too pricey for routine coverage.

By Ned Pagliarulo • Oct. 5, 2018

Roche looks to wider market for Hemlibra with key approval

The hemophilia A drug is now OK'd for patients without inhibitors, who represent about 70% of the total population with that blood disorder.

By Jacob Bell • Oct. 4, 2018

Intermountain's Liljenquist on price transparency, insulin and having 3 brothers with diabetes

The man behind the push for Civica Rx talks about how he hopes the venture will force transparency across the healthcare sector.

By Samantha Liss • Oct. 3, 2018

FDA could set record low for drug marketing warning letters — again

After sending just five letters last year, the FDA office responsible for regulating prescription drug marketing has sent four letters so far in 2018.

By Andrew Dunn • Oct. 3, 2018

Paratek eyes 800 key hospital accounts for new antibiotic's rollout

The pharma shed its clinical-stage title on Tuesday as the FDA approved Nuzyra along with another of its drugs.

By Jacob Bell • Oct. 3, 2018

In reversal, GSK to restart limited payments to doctors

It's a step back from a 2013 pledge that made the British drugmaker an outlier among its industry peers.

By Ned Pagliarulo • Oct. 3, 2018

Lilly's migraine drug wins US approval, pressuring rivals Amgen, Teva

Two rival drugs are already OK'd for sale, setting the migraine market up for fierce competition. Who wins out may depend on how payers react.

By Ned Pagliarulo • Sept. 27, 2018

Pharma advertising in 2018: TV, midterms and specialty drugs

Magna Global expects 2018 to be a banner year for advertising spend, with pharma being one of the largest contributors.

By Jacob Bell • Sept. 26, 2018

ICER finds top asthma biologics overpriced

A draft report from the influential drug pricing group deemed Fasenra, Nucala, Cinqair, Xolair and the still-under-review Dupixent too costly, despite benefits. 

By Andrew Dunn • Sept. 26, 2018

New York regulator warns CVS-Aetna merger could raise prices

The state's top financial watchdog said the pharmacy chain's PBM would have an incentive to give the largest drug discounts to Aetna members.

By Samantha Liss • Sept. 26, 2018

Gilead creates subsidiary to sell generic versions of hep C blockbusters

Asegua Therapeutics will sell authorized generics of Harvoni and Epclusa at an annual list price of $24,000 for the most common course of therapy.

By Jacob Bell • Sept. 24, 2018

Foundation Med advances liquid biopsy ambition with new test

Launch of FoundationOne Liquid will expand the Roche-owned firm's liquid biopsy offerings as demand for blood-based cancer testing grows.

By Ned Pagliarulo • Sept. 24, 2018

UK High Court OKs Avastin off-label use in wet AMD

Doctors in the north of England have won the right to use Avastin to treat wet age-related macular degeneration.

By Suzanne Elvidge • Sept. 24, 2018

Amgen faces a bigger European challenge to Neulasta

Three biosimilar competitors to the blockbuster drug received backing from a key European committee last week.

By Suzanne Elvidge • Sept. 24, 2018